Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. More info @ http://www.bigmarketresearch.com/pharmapoint-asthma-global-drug-forecast-and-analysis-to-2023-market Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
Report Description Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the nextgeneration inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. To request more information Visit @ http://www.bigmarketresearch.com/pharmapoint-asthma-global-drug-forecast-andanalysis-to-2023-market
Report Description Key Questions Answered • Asthma symptoms can be controlled in the majority of patients using the current standard therapies. Nevertheless, in around 5-10% of people with asthma, the disease remains symptomatic and inadequately controlled. Therefore, there are considerably high unmet needs within the indication. What are the main unmet needs in this market.Will the drugs under development fulfil the unmet needs of the asthma market? • The current late-stage asthma pipeline is dominated by biologics that target various inflammatory pathways in specific patient subpopulations. Will the late-stage drugs make a significant impact on the asthma market.What strategies are drug developers undertaking to penetrate this difficult but potentially very lucrative market? Feel free to get enquire about report @ http://www.bigmarketresearch.com/report-enquiry/191286